• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Thrombolysis for acute ischemic stroke by tenecteplase in the emergency department of a Moroccan hospital.在摩洛哥一家医院急诊科使用替奈普酶进行急性缺血性卒中溶栓治疗。
Pan Afr Med J. 2015 May 19;21:37. doi: 10.11604/pamj.2015.21.37.6491. eCollection 2015.
2
Complete recovery following intra-arterial tenecteplase administration in a woman with acute ischemic stroke.一名急性缺血性脑卒中女性患者接受动脉内替奈普酶治疗后完全康复。
J Clin Neurosci. 2013 Dec;20(12):1786-8. doi: 10.1016/j.jocn.2012.12.027. Epub 2013 Aug 9.
3
Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke.替奈普酶与阿替普酶在缺血性脑卒中取栓前的比较。
N Engl J Med. 2018 Apr 26;378(17):1573-1582. doi: 10.1056/NEJMoa1716405.
4
Acute ischemic stroke thrombolysis with tenecteplase: An institutional experience from South India.替奈普酶用于急性缺血性卒中溶栓治疗:来自印度南部某机构的经验
Ann Afr Med. 2018 Apr-Jun;17(2):90-93. doi: 10.4103/aam.aam_50_17.
5
A randomized trial of tenecteplase versus alteplase for acute ischemic stroke.替奈普酶与阿替普酶治疗急性缺血性脑卒中的随机试验。
N Engl J Med. 2012 Mar 22;366(12):1099-107. doi: 10.1056/NEJMoa1109842.
6
[Intravenous thrombolysis in ischemic stroke: Therapeutic perspectives].[缺血性卒中的静脉溶栓治疗:治疗前景]
Rev Neurol (Paris). 2015 Dec;171(12):866-75. doi: 10.1016/j.neurol.2015.09.002. Epub 2015 Nov 10.
7
Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion.替奈普酶-组织型纤溶酶原激活剂评估伴已证实闭塞的小面积缺血性脑卒中。
Stroke. 2015 Mar;46(3):769-74. doi: 10.1161/STROKEAHA.114.008504. Epub 2015 Feb 12.
8
Tenecteplase for the treatment of acute ischemic stroke: A review of completed and ongoing randomized controlled trials.替奈普酶治疗急性缺血性脑卒中:已完成和正在进行的随机对照试验综述。
Int J Stroke. 2018 Dec;13(9):885-892. doi: 10.1177/1747493018790024. Epub 2018 Jul 23.
9
Thrombolytic therapy in acute ischemic stroke in Asia: The first prospective evaluation.亚洲急性缺血性卒中的溶栓治疗:首次前瞻性评估。
Clin Neurol Neurosurg. 2006 Sep;108(6):549-52. doi: 10.1016/j.clineuro.2005.09.008. Epub 2005 Nov 9.
10
Tenecteplase versus alteplase for stroke thrombolysis evaluation (TASTE): A multicentre, prospective, randomized, open-label, blinded-endpoint, controlled phase III non-inferiority trial protocol.替奈普酶与阿替普酶用于卒中溶栓评估(TASTE):一项多中心、前瞻性、随机、开放标签、盲终点、对照 III 期非劣效性试验方案。
Int J Stroke. 2023 Jul;18(6):751-756. doi: 10.1177/17474930231154390. Epub 2023 Feb 2.

引用本文的文献

1
[Thrombolysis alert in ischemic stroke: experience of the international private clinic Al Badie in Fez (cross-sectional study of 60 cases)].[缺血性卒中的溶栓警报:非斯国际私立诊所阿尔巴迪的经验(60例横断面研究)]
Pan Afr Med J. 2024 Apr 4;47:167. doi: 10.11604/pamj.2024.47.167.42376. eCollection 2024.
2
Comprehensive Review of Tenecteplase for Thrombolysis in Acute Ischemic Stroke.替奈普酶在急性缺血性脑卒中溶栓治疗中的全面综述。
J Am Heart Assoc. 2024 May 7;13(9):e031692. doi: 10.1161/JAHA.123.031692. Epub 2024 Apr 30.
3
Off-Label Use of Tenecteplase for the Treatment of Acute Ischemic Stroke: A Systematic Review and Meta-analysis.替奈普酶治疗急性缺血性脑卒中的超说明书用药:系统评价和荟萃分析。
JAMA Netw Open. 2022 Mar 1;5(3):e224506. doi: 10.1001/jamanetworkopen.2022.4506.
4
Effectiveness and safety of different doses of tenecteplase in the treatment of acute ischemic stroke: A protocol for systematic review and meta-analysis.不同剂量替奈普酶治疗急性缺血性脑卒中的有效性和安全性的系统评价和荟萃分析方案。
Medicine (Baltimore). 2021 Jan 22;100(3):e23805. doi: 10.1097/MD.0000000000023805.
5
Ischemic stroke in Morocco: a systematic review.摩洛哥的缺血性中风:一项系统综述。
BMC Neurol. 2019 Dec 30;19(1):349. doi: 10.1186/s12883-019-1558-1.
6
Acute ischemic stroke thrombolysis with tenecteplase: An institutional experience from South India.替奈普酶用于急性缺血性卒中溶栓治疗:来自印度南部某机构的经验
Ann Afr Med. 2018 Apr-Jun;17(2):90-93. doi: 10.4103/aam.aam_50_17.
7
Intravenous thrombolysis with rt-PA in stroke: experience of the moroccan stroke unit.rt-PA静脉溶栓治疗中风:摩洛哥中风单元的经验
Pan Afr Med J. 2016 Jul 8;24:207. doi: 10.11604/pamj.2016.24.207.8815. eCollection 2016.

本文引用的文献

1
The Norwegian tenecteplase stroke trial (NOR-TEST): randomised controlled trial of tenecteplase vs. alteplase in acute ischaemic stroke.挪威替奈普酶治疗卒中试验(NOR-TEST):替奈普酶与阿替普酶治疗急性缺血性卒中的随机对照试验
BMC Neurol. 2014 May 15;14:106. doi: 10.1186/1471-2377-14-106.
2
Early outcomes of thrombolysis for acute ischaemic stroke in a South African tertiary care centre.南非一家三级护理中心急性缺血性脑卒中溶栓治疗的早期结果。
S Afr Med J. 2012 May 23;102(6):541-4. doi: 10.7196/samj.5403.
3
A randomized trial of tenecteplase versus alteplase for acute ischemic stroke.替奈普酶与阿替普酶治疗急性缺血性脑卒中的随机试验。
N Engl J Med. 2012 Mar 22;366(12):1099-107. doi: 10.1056/NEJMoa1109842.
4
Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.急性缺血性卒中发病3至4.5小时后使用阿替普酶进行溶栓治疗。
N Engl J Med. 2008 Sep 25;359(13):1317-29. doi: 10.1056/NEJMoa0804656.
5
Hyperacute thrombolysis with IV rtPA of acute ischemic stroke: efficacy and safety profile of 54 patients at a tertiary referral center in a developing country.
Neurol India. 2007 Jan-Mar;55(1):46-9. doi: 10.4103/0028-3886.30426.
6
Thrombolytic therapy in acute ischemic stroke in Asia: The first prospective evaluation.亚洲急性缺血性卒中的溶栓治疗:首次前瞻性评估。
Clin Neurol Neurosurg. 2006 Sep;108(6):549-52. doi: 10.1016/j.clineuro.2005.09.008. Epub 2005 Nov 9.
7
Predictors of major neurologic improvement after thrombolysis in acute stroke.急性卒中溶栓后主要神经功能改善的预测因素
Neurology. 2005 Oct 25;65(8):1169-74. doi: 10.1212/01.wnl.0000180687.75907.4b.
8
A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke.替奈普酶用于急性缺血性卒中的剂量递增安全性初步研究。
Stroke. 2005 Mar;36(3):607-12. doi: 10.1161/01.STR.0000154872.73240.e9. Epub 2005 Feb 3.
9
Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study.静脉注射组织型纤溶酶原激活剂治疗急性中风:阿替普酶逆转中风标准治疗(STARS)研究
JAMA. 2000 Mar 1;283(9):1145-50. doi: 10.1001/jama.283.9.1145.
10
Treating acute stroke patients with intravenous tPA. The OSF stroke network experience.
Stroke. 2000 Jan;31(1):77-81. doi: 10.1161/01.str.31.1.77.

在摩洛哥一家医院急诊科使用替奈普酶进行急性缺血性卒中溶栓治疗。

Thrombolysis for acute ischemic stroke by tenecteplase in the emergency department of a Moroccan hospital.

作者信息

Belkouch Ahmed, Jidane Said, Chouaib Naoufal, Elbouti Anass, Nebhani Tahir, Sirbou Rachid, Bakkali Hicham, Belyamani Lahcen

机构信息

Emergency Department, Mohamed V Military Hospital of Instruction, Faculty of Medicine and Pharmacy, Rabat, Morocco.

出版信息

Pan Afr Med J. 2015 May 19;21:37. doi: 10.11604/pamj.2015.21.37.6491. eCollection 2015.

DOI:10.11604/pamj.2015.21.37.6491
PMID:26405473
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4564430/
Abstract

INTRODUCTION

Thrombolysis has radically changed the prognosis of acute ischemic stroke. Tenecteplase is a modified form of rt-PA with greater specificity for fibrin and a longer half-life. We report the experience of a Moroccan tertiary hospital in thrombolysis using Tenecteplase.

METHODS

We conducted an open prospective study of all patients who were treated with Tenecteplase for an acute ischemic stroke admitted to our emergency department. Tenecteplase was administered intravenously at a dose of 0.4 mg/kg single bolus. The primary outcome measure was the proportion of patients achieving significant early neurological recovery defined as an improvement of 4 or more points on the NIHSS score at 24h.

RESULTS

13 patients had been treated by intravenous thrombolysis. 31% were women. Mean age was 63 years old. The mean NIHSS score at admission was 14.3 and 24h after was at 9.1. The right middle cerebral artery was involved in 69% of cases. The carotid atherosclerosis was predominant 63.3% and the cardio embolic etiology 27%. The mean time to the first medical contact after the onset of symptoms was 3h 30 min. One patient presented a capsulo-lenticular hematoma of 5 mm(3) in the same side of the ischemic stroke.

CONCLUSION

Tenecteplase is a more interesting thrombolytic than alteplase, it seems to be more suitable for thrombolysis in our center.

摘要

引言

溶栓治疗已从根本上改变了急性缺血性卒中的预后。替奈普酶是重组组织型纤溶酶原激活剂(rt-PA)的一种改良形式,对纤维蛋白具有更高的特异性和更长的半衰期。我们报告了一家摩洛哥三级医院使用替奈普酶进行溶栓治疗的经验。

方法

我们对在急诊科接受替奈普酶治疗急性缺血性卒中的所有患者进行了一项开放性前瞻性研究。替奈普酶以0.4mg/kg单次静脉推注给药。主要结局指标是在24小时时美国国立卫生研究院卒中量表(NIHSS)评分改善4分或更多分定义为实现显著早期神经功能恢复的患者比例。

结果

13例患者接受了静脉溶栓治疗。31%为女性。平均年龄为63岁。入院时平均NIHSS评分为14.3,24小时后为9.1。69%的病例累及右侧大脑中动脉。颈动脉粥样硬化占主导地位,为63.3%,心源性栓塞病因占27%。症状发作后至首次医疗接触的平均时间为3小时30分钟。1例患者在缺血性卒中同侧出现了5mm³的豆状核血肿。

结论

替奈普酶是一种比阿替普酶更具优势的溶栓剂,在我们中心似乎更适合用于溶栓治疗。